PTC Therapeutics, Inc. (PTCT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications.
Is PTC Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of October 3, 2026, PTC Therapeutics, Inc. (PTCT) trades at 8.9× earnings (P/E), according to Kaplio. No valuation verdict: it trades at 8.9 times earnings, but its references are not enough for a verdict.
Kaplio overview: PTC Therapeutics, Inc.
Market cap $5B · 52 weeks $62 – $90 (29 % below the high) · P/E 8.9× · 2027 expected P/E 24.1× · Dividend none · Next earnings November 3, 2026 · expected EPS $0.29 · Price as of Oct 3 · accounts published Jul 30.
- Valuation: P/Sales 2.3× (no verdict).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it trades at 8.9 times earnings, but its references are not enough for a verdict.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 8.8 %, fails.
- Total Debt 1.5×, borderline.
- Annual cash burn $8.94, passes.
- Market cap / Cash 2.6×, passes.
Against its peers (reference peers) — PTC Therapeutics, Inc.: P/E 8.8×; EV/EBITDA 8.8×; ROIC 33.4 %; $5.4B. TG Therapeutics, Inc. (P/E 17.8×; EV/EBITDA 63.5×; ROIC 9.9 %; $8.3B), Protagonist Therapeutics, Inc. (P/E 115×; EV/EBITDA —; ROIC -25.2 %; $9.2B), Krystal Biotech, Inc. (P/E 39.0×; EV/EBITDA 33.9×; ROIC 13.1 %; $9.6B).
Profitability
| Return on Equity | -332.49% |
| Return on Invested Capital | 33.37% |
| Return on Assets | 23.55% |
| Gross Margin | 95.85% |
| Operating Margin | 49.49% |
| Net Margin | 39.44% |
Financial Health
| Debt / Equity | -13.19 |
| Current Ratio | 2.35 |
Price Performance
| 1 month | -8.15% |
| 3 months | -28.14% |
| Year-to-date | -16.21% |
| 1 year | -1.77% |
| 3 years | +194.68% |
| 5 years | +72.96% |
Related companies: ALKS · ARWR · KRYS · MTSR · PCVX
Explore sector: Healthcare · Biotechnology
More sections of PTCT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks